{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:05:27Z","timestamp":1777363527078,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-024-01169-4","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T23:19:09Z","timestamp":1731539949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of 68[Ga]Ga-DOTA-TATE PET\/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours"],"prefix":"10.1186","volume":"14","author":[{"given":"Karolina","family":"Morawiec-S\u0142awek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Opali\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wioletta","family":"Lenda-Tracz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Sitarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kurzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Stefa\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kolasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Sowa-Staszczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-4689","authenticated-orcid":false,"given":"Alicja","family":"Hubalewska-Dydejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"7","key":"1169_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304.","journal-title":"Ann Oncol"},{"issue":"3","key":"1169_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5603\/EP.a2022.0049","volume":"73","author":"B Kos-Kud\u0142a","year":"2022","unstructured":"Kos-Kud\u0142a B, Foltyn W, Malczewska A, Bednarczuk T, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) [Aktualizacja zalece\u0144 og\u00f3lnych dotycz\u0105cych post\u0119powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych uk\u0142adu pokarmowego (rekomendowane przez Polsk\u0105 Sie\u0107 Guz\u00f3w Neuroendokrynnych)]. Endokrynol Pol. 2022;73(3):387\u2013454. https:\/\/doi.org\/10.5603\/EP.a2022.0049.","journal-title":"Endokrynol Pol"},{"issue":"13","key":"1169_CR3","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3390\/cancers15133483","volume":"15","author":"L Piscopo","year":"2023","unstructured":"Piscopo L, Zampella E, Pellegrino S, Volpe F, et al. Diagnosis, management and theragnostic approach of gastro-entero-pancreatic neuroendocrine neoplasms. Cancers (Basel). 2023;15(13):3483. https:\/\/doi.org\/10.3390\/cancers15133483.","journal-title":"Cancers (Basel)"},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","volume":"440","author":"M Papotti","year":"2002","unstructured":"Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1\u20135 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch Int J Pathol. 2002;440:461\u201375. https:\/\/doi.org\/10.1007\/s00428-002-0609-x.","journal-title":"Virchows Arch Int J Pathol"},{"issue":"4","key":"1169_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000486096","volume":"106","author":"WT Zandee","year":"2018","unstructured":"Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines. Neuroendocrinology. 2018;106(4):357\u201365. https:\/\/doi.org\/10.1159\/000486096.","journal-title":"Neuroendocrinology"},{"issue":"12","key":"1169_CR6","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.3390\/ijms20123049","volume":"20","author":"AK Stueven","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019;20(12):3049. https:\/\/doi.org\/10.3390\/ijms20123049.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"1169_CR7","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al. PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1169_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/ERC-15-0490","volume":"23","author":"ME Caplin","year":"2016","unstructured":"Caplin ME, Pavel M, \u0106wik\u0142a JB, et al. CLARINET Investigators: Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191\u20139. https:\/\/doi.org\/10.1530\/ERC-15-0490.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1169_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589\u201397. https:\/\/doi.org\/10.1002\/cncr.29099.","journal-title":"Cancer"},{"issue":"13","key":"1169_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.929391","volume":"15","author":"M Opali\u0144ska","year":"2022","unstructured":"Opali\u0144ska M, Morawiec-S\u0142awek K, Kania-Kuc A, et al. Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET\/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol (Lausanne). 2022;15(13): 929391. https:\/\/doi.org\/10.3389\/fendo.2022.929391.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1169_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/diagnostics13040606","volume":"13","author":"L Urso","year":"2023","unstructured":"Urso L, Castello A, Treglia G, Panareo S, et al. Relevance of volumetric parameters applied to [68Ga]Ga-DOTATOC PET\/CT in NET patients treated with PRRT. Diagnostics (Basel). 2023;13(4):606. https:\/\/doi.org\/10.3390\/diagnostics13040606.","journal-title":"Diagnostics (Basel)"},{"key":"1169_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.coemr.2021.03.017","volume":"18","author":"IM Modlin","year":"2021","unstructured":"Modlin IM, Kidd M, Bodei L, Malczewska A, Kitz A, Oberg K. Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: \u201cThe times they are a changin.\u201d Curr Opin Endocrine Metab Res. 2021;18:243\u201353. https:\/\/doi.org\/10.1016\/j.coemr.2021.03.017.","journal-title":"Curr Opin Endocrine Metab Res"},{"issue":"8","key":"1169_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.771912","volume":"26","author":"J Hou","year":"2021","unstructured":"Hou J, Yang Y, Chen N, Chen D, Hu S. Prognostic value of volume-based parameters measured by SSTR PET\/CT in neuroendocrine tumors: a systematic review and meta-analysis. Front Med (Lausanne). 2021;26(8): 771912. https:\/\/doi.org\/10.3389\/fmed.2021.771912.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1169_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2967\/jnumed.119.228072","volume":"61","author":"E Ilan","year":"2020","unstructured":"Ilan E, Velikyan I, Sandstr\u00f6m M, et al. Tumor-to-Blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68-Ga-DOTATOC and 68-Ga-DOTATATE. J Nucl Med. 2020;61(2):217\u201321. https:\/\/doi.org\/10.2967\/jnumed.119.228072.","journal-title":"J Nucl Med"},{"issue":"4","key":"1169_CR15","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00259-019-04439-9","volume":"47","author":"J Graf","year":"2020","unstructured":"Graf J, Pape UF, Henning J, et al. Prognostic Significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47(4):881\u201394. https:\/\/doi.org\/10.1007\/s00259-019-04439-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1169_CR16","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12020-017-1364-8","volume":"57","author":"F Grillo","year":"2017","unstructured":"Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G, Vanoli A, Fiocca R, Mastracci L. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? Endocrine. 2017;57(3):494\u2013502. https:\/\/doi.org\/10.1007\/s12020-017-1364-8.","journal-title":"Endocrine"},{"issue":"7","key":"1169_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.119.236935","volume":"61","author":"E Pauwels","year":"2020","unstructured":"Pauwels E, Van Binnebeek S, Vandecaveye V, Baete K, Vanbilloen H, Koole M, Mottaghy FM, Haustermans K, Clement PM, Nackaerts K, Van Cutsem E, Verslype C, Deroose CM. Inflammation-based index and 68Ga-DOTATOC PET-derived uptake and volumetric parameters predict outcome in neuroendocrine tumor patients treated with 90Y-DOTATOC. J Nucl Med. 2020;61(7):1014\u201320. https:\/\/doi.org\/10.2967\/jnumed.119.236935.","journal-title":"J Nucl Med"},{"issue":"11","key":"1169_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","volume":"14","author":"J Hofland","year":"2018","unstructured":"Hofland J, Zandee WT, de Herder WW. Role of biomarker tests for diagnosis of neuroendocrine tumours. Nat Rev Endocrinol. 2018;14(11):656\u201369. https:\/\/doi.org\/10.1038\/s41574-018-0082-5.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1169_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1210\/jc.2018-01214","volume":"104","author":"JRM Black","year":"2019","unstructured":"Black JRM, Atkinson SR, Singh A, Evans J, Sharma R. The inflammation-based index can predict response and improve patient selection in NETs treated with PRRT: a pilot study. J Clin Endocrinol Metab. 2019;104(2):285\u201392. https:\/\/doi.org\/10.1210\/jc.2018-01214.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1169_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/diagnostics11020192","volume":"11","author":"P Mapelli","year":"2021","unstructured":"Mapelli P, Partelli S, Salgarello M, Doraku J, et al. Dual Tracer 68Ga-DOTATOC and 18F-FDG PET improve preoperative evaluation of aggressiveness in resectable pancreatic neuroendocrine neoplasms. Diagnostics (Basel). 2021;11(2):192. https:\/\/doi.org\/10.3390\/diagnostics11020192.","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"1169_CR21","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.21037\/jgo-22-1011","volume":"14","author":"A Mohamed","year":"2023","unstructured":"Mohamed A, Asa SL, Lee Z, Tirumani SH, Li Q, Avril N, Bajor D, Mahipal A, Chakrabarti S, Selfridge JE, Kardan A. The predictive impact of dual somatostatin receptor\/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience. J Gastrointest Oncol. 2023;14(2):1087\u201394. https:\/\/doi.org\/10.21037\/jgo-22-1011.","journal-title":"J Gastrointest Oncol."},{"issue":"9","key":"1169_CR22","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2967\/jnumed.120.257659","volume":"62","author":"DL Chan","year":"2021","unstructured":"Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. Dual PET imaging in bronchial neuroendocrine neoplasms: the NETPET score as a prognostic biomarker. J Nucl Med. 2021;62(9):1278\u201384. https:\/\/doi.org\/10.2967\/jnumed.120.257659.","journal-title":"J Nucl Med"},{"issue":"1","key":"1169_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2967\/jnumed.116.178095","volume":"58","author":"E Panagiotidis","year":"2017","unstructured":"Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, et al. Comparison of the impact of 68Ga-DOTATATE and 18F-FDG PET\/CT on clinical management in patients with neuroendocrine tumors. J Nucl Med. 2017;58(1):91\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.178095.","journal-title":"J Nucl Med"},{"issue":"1","key":"1169_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","volume":"10","author":"YI Kim","year":"2020","unstructured":"Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, Hong SM, Ryoo BY, Ryu JS. Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res. 2020;10(1):63. https:\/\/doi.org\/10.1186\/s13550-020-00651-z.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1169_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1634\/theoncologist.2020-0165","volume":"26","author":"H Lee","year":"2021","unstructured":"Lee H, Eads JR, Pryma DA. 68 Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors. Oncologist. 2021;26(1):21\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2020-0165.","journal-title":"Oncologist"},{"issue":"4","key":"1169_CR26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2478\/raon-2023-0055","volume":"57","author":"M Ingenerf","year":"2023","unstructured":"Ingenerf M, Karim H, Auernhammer C, Zacherl M, Wenter V, Winkelmann M, Ricke J, Berger F, Schmid-Tannwald C. Quantitative SSTR-PET\/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Radiol Oncol. 2023;57(4):436\u201345. https:\/\/doi.org\/10.2478\/raon-2023-0055.","journal-title":"Radiol Oncol"},{"issue":"8","key":"1169_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/MNM.0000000000000522","volume":"37","author":"U Abdulrezzak","year":"2016","unstructured":"Abdulrezzak U, Kurt YK, Kula M, et al. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET\/CT on the basis of volumetric parameters in neuroendocrine tumors. Nucl Med Commun. 2016;37(8):874\u201381. https:\/\/doi.org\/10.1097\/MNM.0000000000000522.","journal-title":"Nucl Med Commun"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2310\/7290.2014.00009","volume":"13","author":"W Koch","year":"2014","unstructured":"Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, Bartenstein P, Haug AR. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging. 2014;13:1\u201310.","journal-title":"Mol Imaging"},{"issue":"3","key":"1169_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, Mier W, Haberkorn U, Giesel FL. SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313\u20138. https:\/\/doi.org\/10.1007\/s11307-014-0795-3.","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"1169_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1309\/AJCPQ55SKOCYFZHN","volume":"143","author":"C Shi","year":"2015","unstructured":"Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am J Clin Pathol. 2015;143(3):398\u2013404. https:\/\/doi.org\/10.1309\/AJCPQ55SKOCYFZHN.","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"1169_CR31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","volume":"51","author":"AR Haug","year":"2010","unstructured":"Haug AR, Auernhammer CJ, W\u00e4ngler B, Schmidt GP, Uebleis C, G\u00f6ke B, Cumming P, Bartenstein P, Tiling R, Hacker M. 68Ga-DOTATATE PET\/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349\u201356. https:\/\/doi.org\/10.2967\/jnumed.110.075002.","journal-title":"J Nucl Med"},{"issue":"12","key":"1169_CR32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52(12):1864\u201370. https:\/\/doi.org\/10.2967\/jnumed.111.091165.","journal-title":"J Nucl Med"},{"issue":"1","key":"1169_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(1):50\u20136. https:\/\/doi.org\/10.1007\/s00259-011-1937-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1169_CR34","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","volume":"154","author":"A Tirosh","year":"2018","unstructured":"Tirosh A, Papadakis GZ, Millo C, Hammoud D, Sadowski SM, Herscovitch P, Pacak K, Marx SJ, Yang L, Nockel P, Shell J, Green P, Keutgen XM, Patel D, Nilubol N, Kebebew E. Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors. Gastroenterology. 2018;154(4):998-1008.e1. https:\/\/doi.org\/10.1053\/j.gastro.2017.11.008.","journal-title":"Gastroenterology"},{"issue":"11","key":"1169_CR35","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00259-019-04455-9","volume":"46","author":"A Toriihara","year":"2019","unstructured":"Toriihara A, Baratto L, Nobashi T, et al. Prognostic value of somatostatin receptor expressing tumor volume calculated from 68 Ga-DOTATATE PET\/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019;46(11):2244\u201351. https:\/\/doi.org\/10.1007\/s00259-019-04455-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1169_CR36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4149\/neo_2018_180328N209","volume":"66","author":"J Ohnona","year":"2019","unstructured":"Ohnona J, Nataf V, Gauthe M, Balogova S, Belissant Benesty O, Zhang-Yin J, Talbot JN, Montravers F. Prognostic value of functional tumor burden on 68Ga-DOTATOC PET\/CT in patients with pancreatic neuro-endocrine tumors. Neoplasma. 2019;66(1):140\u20138. https:\/\/doi.org\/10.4149\/neo_2018_180328N209.","journal-title":"Neoplasma"},{"issue":"7","key":"1169_CR37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.121.262652","volume":"63","author":"P Thuillier","year":"2022","unstructured":"Thuillier P, Liberini V, Grimaldi S, Rampado O, Gallio E, Santi B, Arvat E, Piovesan A, Filippi R, Abgral R, Molinari F, Deandreis D. Prognostic value of whole-body PET volumetric parameters extracted from 68Ga-DOTATOC PET\/CT in well-differentiated neuroendocrine tumors. J Nucl Med. 2022;63(7):1014\u201320. https:\/\/doi.org\/10.2967\/jnumed.121.262652.","journal-title":"J Nucl Med"},{"issue":"1","key":"1169_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe JR, Merchant NB, Conrad C, Keutgen XM, et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas. 2020;49(1):1\u201333. https:\/\/doi.org\/10.1097\/MPA.0000000000001454.","journal-title":"Pancreas"},{"issue":"15","key":"1169_CR39","doi-asserted-by":"publisher","first-page":"175883592311793","DOI":"10.1177\/17588359231179310","volume":"9","author":"P Bourdeleau","year":"2023","unstructured":"Bourdeleau P, Couvelard A, Ronot M, Lebtahi R, Hentic O, Ruszniewski P, Cros J, de Mestier L. Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms. Ther Adv Med Oncol. 2023;9(15):17588359231179310. https:\/\/doi.org\/10.1177\/17588359231179310.","journal-title":"Ther Adv Med Oncol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01169-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01169-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:08:02Z","timestamp":1731542882000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01169-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01169-4","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Commission for Ethics in Scientific Research at the Jagiellonian University Medical College in Krakow (approval no 118.0043.1.1.2024). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication."}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}